Our research focuses on understanding the involvement of the immune system in heart failure, and on the significance of innovative immunomodulating treatment strategies for a range of vascular and/or heart muscle diseases. In this context, we examine the healing power of cardiac-derived proliferating cells (CardAPs), mesenchymal stromal cells, T regulatory cells, B cells and immunomodulating pharmaca, particularly in inflammatory cardiomyopathy/myocarditis, heart failure with preserved ejection fraction, and post-myocardial infarction. The impact of those immunomodulating strategies on endothelial activation, endothelial-to-mesenchymal transition, and function is another point of our research.
Additionally, we investigate the mode of action of transplanted stem cells in ischemic heart failure, their interaction with the damaged myocardium and the characteristics of the injured heart that determine their survival, engraftment and cardiogenic differentiation capacity. Finally, as an alternative to stem cells for cell therapy, we generate cardiomyocytes via direct reprogramming of cardiac fibroblasts into cardiomyocytes.
- "Experimental Immunocardiology" (Prof. Dr. Carsten Tschöpe: BCRT, Charité)
- "Cardiomyocyte Restoration and Matrix Support" (Prof. Dr. Christoph Stamm: BCRT, Charité, DHZB)